Antonios A Koutalos1, George I Chalatsis2, Georgios Varsanis2, Konstantinos N Malizos2, Theofilos Karachalios2. 1. Department of Orthopaedic Surgery & Musculoskeletal Trauma, Faculty of Medicine, University of Thessaly, Biopolis, 41500, Larissa, Greece. akoutmed@gmail.com. 2. Department of Orthopaedic Surgery & Musculoskeletal Trauma, Faculty of Medicine, University of Thessaly, Biopolis, 41500, Larissa, Greece.
Abstract
PURPOSE: Hip fractures are associated with functional decline and increased mortality. The aim of this study was to investigate the effect of zoledronic acid and high-dose vitamin D on function and mortality after hip fractures. PATIENTS AND METHODS: Forty-five patients received zoledronic acid and high dose of vitamin D during hospitalization after fracture management. These patients were compared with a control group of 46 patients. Pre- and postoperative prospectively collected data including ASA score, Charlson comorbidity score, presence of dementia, Vitamin D, and the Barthel index were available. Final follow-up was performed after one year. Primary outcome was patients' function at final follow-up as measured with Barthel index score. Secondary outcomes included mortality, assessment of pain, and complications. RESULTS: Barthel index score at final follow-up was decreased in both groups. There was no significant difference in Barthel index between the two groups (15.5 ± 5.0 vs 15.8 ± 5.8, p = 0.850). However, the Barthel index in the control group decreased beyond the smallest detectable change (3 points). Mortality was statistically different between groups (8.8% vs 28.2%, p = 0.047). Complications and pain at final follow-up were not different between groups. Multivariate analysis revealed that preoperative Barthel index and Charlson comorbidity score independently affected function at final follow-up. Logistic regression analysis disclosed that not receiving active treatment and complications were associated with increased mortality. CONCLUSIONS: Medical treatment after surgical management of hip fractures results in reduced mortality and lessens the functional decline associated with these fractures.
PURPOSE: Hip fractures are associated with functional decline and increased mortality. The aim of this study was to investigate the effect of zoledronic acid and high-dose vitamin D on function and mortality after hip fractures. PATIENTS AND METHODS: Forty-five patients received zoledronic acid and high dose of vitamin D during hospitalization after fracture management. These patients were compared with a control group of 46 patients. Pre- and postoperative prospectively collected data including ASA score, Charlson comorbidity score, presence of dementia, Vitamin D, and the Barthel index were available. Final follow-up was performed after one year. Primary outcome was patients' function at final follow-up as measured with Barthel index score. Secondary outcomes included mortality, assessment of pain, and complications. RESULTS: Barthel index score at final follow-up was decreased in both groups. There was no significant difference in Barthel index between the two groups (15.5 ± 5.0 vs 15.8 ± 5.8, p = 0.850). However, the Barthel index in the control group decreased beyond the smallest detectable change (3 points). Mortality was statistically different between groups (8.8% vs 28.2%, p = 0.047). Complications and pain at final follow-up were not different between groups. Multivariate analysis revealed that preoperative Barthel index and Charlson comorbidity score independently affected function at final follow-up. Logistic regression analysis disclosed that not receiving active treatment and complications were associated with increased mortality. CONCLUSIONS: Medical treatment after surgical management of hip fractures results in reduced mortality and lessens the functional decline associated with these fractures.
Authors: Richard Eastell; Dennis M Black; Steven Boonen; Silvano Adami; Dieter Felsenberg; Kurt Lippuner; Steven R Cummings; Pierre D Delmas; Lisa Palermo; Peter Mesenbrink; Jane A Cauley Journal: J Clin Endocrinol Metab Date: 2009-06-30 Impact factor: 5.958
Authors: Patrick Haentjens; Jay Magaziner; Cathleen S Colón-Emeric; Dirk Vanderschueren; Koen Milisen; Brigitte Velkeniers; Steven Boonen Journal: Ann Intern Med Date: 2010-03-16 Impact factor: 25.391
Authors: J D Adachi; K W Lyles; C S Colón-Emeric; S Boonen; C F Pieper; C Mautalen; L Hyldstrup; C Recknor; L Nordsletten; K A Moore; C Bucci-Rechtweg; G Su; E F Eriksen; J S Magaziner Journal: Osteoporos Int Date: 2011-01-20 Impact factor: 4.507
Authors: Carl F Pieper; Cathleen Colon-Emeric; John Caminis; Kathleen Betchyk; Jie Zhang; Cheri Janning; John Shostak; Meryl S LeBoff; Robert R Heaney; Kenneth W Lyles Journal: Am J Geriatr Pharmacother Date: 2007-12
Authors: Peter D Papapetrou; Maria Triantaphyllopoulou; Helen Karga; Panagiotis Zagarelos; Kyriakos Aloumanis; Eleni Kostakioti; George Vaiopoulos Journal: J Bone Miner Metab Date: 2007-04-20 Impact factor: 2.626